Strengths of response adaptive trial design include more efficient assessment of efficacy, limited risk of RCTs that find potential harm (by decreasing the sample size compared to frequentist statistical trial design), decreased time and expense (i.e., more efficient futility rules), improved drug dose selection and earlier completion of negative RCTs.
However, the overall efficacy of standard antivirus therapy in multigenotype subjects remained low (~43%) that warns the need of more efficient drugs with better efficacy.
First clinical trials have indicated that 89Zr-immuno-PET might be an attractive tool for tumor detection and to allow better understanding of mAb therapy efficacy, more efficient mAb development, and more patient-tailored therapy [1, 2].
The use of genotype information in clinical psychopharmacology could potentially help clinicians avoid the standard trial and error approach, and allow a more efficient way to maximize efficacy and minimize toxicity [1] [3] as is done in certain situations with cancer treatment [4].
In recent years, researchers have developed some bioinformatic methods to infer drug target interactions [ 10- 15], which provide opportunities to conduct more efficient research on the efficacy of the entire formula.
Although the use of response rate may be more efficient in determining drug efficacy, it does appear to be particularly susceptible to a high placebo effect; in this regard, remission rates may be a more appropriate and clinically meaningful primary endpoint (Winter et al. 2006).
Online marketers increasingly use a much more efficient method to test the efficacy of their frames.
Organophosphorus nerve agents are irreversible inhibitors of acetylcholinesterase. Current treatment of nerve agent poisoning has limited efficacy and more efficient medical countermeasures need to be developed.
Interestingly, low frequencies were more efficient in increasing the killing efficacy of antimicrobials than higher ones (Qian, Sagers and Pitt 1999).
The enhanced tumor accumulation of PheoA-ss-CNPs enabled tumor therapeutic efficacy that was more efficient than free PheoA in tumor-bearing mice.
